JP6937309B2 - ハイブリッドプロモーターおよびその使用 - Google Patents

ハイブリッドプロモーターおよびその使用 Download PDF

Info

Publication number
JP6937309B2
JP6937309B2 JP2018536777A JP2018536777A JP6937309B2 JP 6937309 B2 JP6937309 B2 JP 6937309B2 JP 2018536777 A JP2018536777 A JP 2018536777A JP 2018536777 A JP2018536777 A JP 2018536777A JP 6937309 B2 JP6937309 B2 JP 6937309B2
Authority
JP
Japan
Prior art keywords
sequence
protein
seq
cells
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018536777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503179A (ja
JP2019503179A5 (enExample
Inventor
ティー． マクグルー，ジェフリー
ティー． マクグルー，ジェフリー
エス． スミディット，ポーライン
エス． スミディット，ポーライン
オン，イーチェン
Original Assignee
ジャスト−エヴォテック バイオロジックス、インコーポレイテッド
ジャスト−エヴォテック バイオロジックス、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャスト−エヴォテック バイオロジックス、インコーポレイテッド, ジャスト−エヴォテック バイオロジックス、インコーポレイテッド filed Critical ジャスト−エヴォテック バイオロジックス、インコーポレイテッド
Publication of JP2019503179A publication Critical patent/JP2019503179A/ja
Publication of JP2019503179A5 publication Critical patent/JP2019503179A5/ja
Application granted granted Critical
Publication of JP6937309B2 publication Critical patent/JP6937309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018536777A 2016-01-27 2017-01-26 ハイブリッドプロモーターおよびその使用 Active JP6937309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662388391P 2016-01-27 2016-01-27
US62/388,391 2016-01-27
PCT/US2017/015130 WO2017132376A1 (en) 2016-01-27 2017-01-26 Hybrid promoter and uses thereof

Publications (3)

Publication Number Publication Date
JP2019503179A JP2019503179A (ja) 2019-02-07
JP2019503179A5 JP2019503179A5 (enExample) 2021-04-22
JP6937309B2 true JP6937309B2 (ja) 2021-09-22

Family

ID=58044162

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536777A Active JP6937309B2 (ja) 2016-01-27 2017-01-26 ハイブリッドプロモーターおよびその使用

Country Status (5)

Country Link
US (1) US11028410B2 (enExample)
EP (1) EP3408397B1 (enExample)
JP (1) JP6937309B2 (enExample)
ES (1) ES2823173T3 (enExample)
WO (1) WO2017132376A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11098310B2 (en) * 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
EP3856910B1 (en) * 2018-09-24 2024-11-20 Merck Sharp & Dohme LLC Expression vectors for eukaryotic expression systems
PT115073A (pt) 2018-10-09 2020-05-29 Inst De Biologia Molecular E Celular Ibmc Ácido nucleico para ativar a expressão e a produção de proteínas
WO2022204067A1 (en) * 2021-03-24 2022-09-29 Dna Twopointo Inc. Tetracycline-inducible expression systems
CA3266599A1 (en) 2022-09-07 2024-11-07 Quantitative Biosciences Inc UNIQUE VARIABLE DOMAIN ANTIBODIES SPECIFIC TO FENTANYL AND USE IN A CONTINUOUS AGGLUTINATION TEST
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
CA1341482C (en) 1984-10-31 2005-05-10 Paul A. Luciw Process for preparing fragments of aids-associated retroviruses
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE68925893T2 (de) 1988-07-23 1996-08-08 Delta Biotechnology Ltd Sekretorische leader-sequenzen
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
WO2000055371A1 (en) 1999-03-18 2000-09-21 Human Genome Sciences, Inc. 27 human secreted proteins
US5972650A (en) * 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US6022952A (en) 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
EP1132479B1 (en) 1998-11-20 2009-04-22 Fuso Pharmaceutical Industries Ltd. Protein expression vector and utilization thereof
US20050005310A1 (en) 1999-07-12 2005-01-06 Genentech, Inc. Expression vectors and methods
GB2355459B (en) 1999-11-29 2001-09-26 Isis Innovation A dominant conditional lethal genetic system
DK1332222T3 (da) 2000-11-03 2009-07-06 Genentech Inc Stofskifteændringer i fermenteringer der udtrykker rekombinante proteiner
AU2003298674A1 (en) 2002-11-14 2004-06-15 Genentech Inc Intron fusion construct and method of using for selecting high-expressing production cell lines
BRPI0408246A (pt) 2003-03-11 2006-03-01 Applied Research Systems vetores de expressão que compreendem o promotor ie2 do mcmv
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
KR101078202B1 (ko) 2003-08-14 2011-11-01 와이어쓰 엘엘씨 재조합 루브리신 분자 및 이의 용도
KR20050022071A (ko) 2003-08-26 2005-03-07 삼성에스디아이 주식회사 플라즈마 디스플레이 패널
US20080032300A1 (en) 2004-12-02 2008-02-07 Laboratories Serono S.A. Lupac Bifunctional Marker and Its Use in Protein Production
CA2590284A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
WO2007092370A2 (en) 2006-02-03 2007-08-16 Wyeth Lingo-1 structure
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
EP2046953A4 (en) 2006-08-07 2010-01-27 Synageva Biopharma Corp HYBRID PROMOTERS
FR2910490B1 (fr) 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
KR100884214B1 (ko) * 2007-04-04 2009-02-19 주식회사 마크로젠 Ｃａｅｖ-계 벡터 시스템
RU2491344C2 (ru) 2007-06-29 2013-08-27 Ф.Хоффманн-Ля Рош Аг Промотор
US8771988B2 (en) 2007-10-12 2014-07-08 Hoffmann-La Roche Inc. Protein expression from multiple nucleic acids
EP2203180B1 (en) 2007-10-22 2012-11-21 Merck Serono S.A. Single ifn-beta fused to a mutated igg fc fragment
AU2008333131B2 (en) 2007-12-07 2013-10-24 Merck Serono S/A Humanized antibody molecules specific for IL-31
US8795981B2 (en) 2008-08-08 2014-08-05 Molecular Devices, Llc Cell detection
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
GB201004143D0 (en) * 2010-03-12 2010-04-28 Isis Innovation Promoter sequence for DNA and viral vectors
CN107090040A (zh) 2011-05-27 2017-08-25 艾伯维生物技术有限公司 Dac hyp组合物和方法
US9809652B2 (en) 2011-08-08 2017-11-07 Abbvie Biotherapeutics Inc. Methods of treating progressive forms of multiple sclerosis comprising subcutaneously administering daclizumab
CA2857298A1 (en) 2011-11-30 2013-06-06 Abbvie Biotherapeutics Inc. Vectors and host cells comprising a modified sv40 promoter for protein expression
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CA3149402A1 (en) 2011-12-22 2013-06-27 F. Hoffman-La Roche Ag Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
KR101494072B1 (ko) 2012-03-12 2015-02-17 한화케미칼 주식회사 변이된 글루타민 합성효소 유전자를 포함하는 벡터 및 이를 이용한 목적 단백질의 생산방법
CN104884473B (zh) 2012-05-22 2019-12-03 百时美施贵宝公司 Il-17a/f il-23双特异性抗体及其应用
EP2674495A1 (en) 2012-06-14 2013-12-18 Sanofi CHO expression system
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
CN104718291B (zh) * 2012-10-10 2020-12-01 中外制药株式会社 经修饰的宿主细胞的建立方法
US9290552B2 (en) 2012-12-21 2016-03-22 Dna Twopointo, Inc. Fluorescent and colored proteins and methods for using them
KR20150125994A (ko) 2013-03-08 2015-11-10 뉴클론 바이오로직스 피티와이 엘티디 세포 발현 시스템
BR112016007547A2 (pt) 2013-10-07 2018-01-23 Prestige Biopharma Pte. Ltd. ?vetor de expressão bicistrônico para expressão de anticorpos e método para a produção de anticorpos usando o mesmo?
CA3246595A1 (en) 2014-04-09 2025-07-08 Dna Twopointo Inc Enhanced polynucleotide constructs for eukaryotic gene expression
US10927384B2 (en) 2014-04-09 2021-02-23 Dna Twopointo Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
US11280790B2 (en) 2016-10-04 2022-03-22 Svar Life Science Ab System and products for improved quantification of ADCC activity
US20240076332A1 (en) 2016-10-04 2024-03-07 Svar Life Science Ab FGF21 Responsive Reporter Gene Cell Line

Also Published As

Publication number Publication date
EP3408397A1 (en) 2018-12-05
EP3408397B1 (en) 2020-07-15
ES2823173T3 (es) 2021-05-06
JP2019503179A (ja) 2019-02-07
WO2017132376A1 (en) 2017-08-03
US20190055580A1 (en) 2019-02-21
US11028410B2 (en) 2021-06-08

Similar Documents

Publication Publication Date Title
JP6937309B2 (ja) ハイブリッドプロモーターおよびその使用
US10975151B2 (en) ASPGR antibodies and uses thereof
US11685933B2 (en) Inducible expression from transposon-based vectors and uses
JP2019503179A5 (enExample)
US11692193B2 (en) Expression from transposon-based vectors and uses
KR20140012035A (ko) 단백질의 생산 방법
WO2020260327A1 (en) Mammalian cell lines with sirt-1 gene knockout
CN112912392A (zh) 利用重组酶介导的盒式交换的多特异性抗体筛选方法
US20190346456A1 (en) High throughput antibody variant screening method
JP2017530718A (ja) 宿主細胞における異種由来遺伝子の発現を改善するためのプロモーター及び調節エレメント
JP2022537202A (ja) 所定の構成の複数の発現カセットの標的指向性組込みによって多価二重特異性抗体発現細胞を作製するための方法
JP2022537334A (ja) 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法
US20240035037A1 (en) Transposon-based vectors and uses
TW202321312A (zh) 包含基於ｍｈｃ或ｍｈｃ樣蛋白的異源二聚體的二價雙特異性嵌合抗體
US20110313138A1 (en) Method for Producing Proteins
CN101180316B (zh) 在哺乳动物宿主细胞中高水平表达重组抗体
US20220281957A1 (en) Modified human variable domains
WO2025128343A1 (en) Protein expression using trans-splicing and split selectable markers
WO2025190332A1 (zh) 特异性结合nkg2a抗原和pd-l1抗原的多特异性抗体及其应用
JP2010536345A (ja) 新規な方法および細胞系
HK40040827A (en) Modulating lactogenic activity in mammalian cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210803

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210830

R150 Certificate of patent or registration of utility model

Ref document number: 6937309

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250